Zydus Cadila has received the final approval from the USFDA to market Clindamycin Phosphate Topical Solution USP (Cleocin T), 1%. Clindamycin is an antibiotic which works by stopping the growth Of bacteria. It is used to treat acne and helps to decreasethe number of acnelesions. It will be manufactured at group's Topical manufacturing facility at Ahmedabad.

In line with this, the group now has204 approvals and hasso far filed over 330 ANDAs since the commencement of the filing processin FY 2003-04.

Shares of the company gained Rs 7.15, or 2.04%, to trade at Rs 357.20. The total volume of shares traded was 33,746 at the BSE (10.48 a.m., Tuesday).